Elisabetta Abruzzese

Rome, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 198 publications

Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network.

Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network.

Journal: Clinical lymphoma, myeloma & leukemia
Published: June 09, 2026

Reframing chronic myeloid leukemia outcomes beyond survival: a perspective of quality of life and patient-centered data.

Reframing chronic myeloid leukemia outcomes beyond survival: a perspective of quality of life and patient-centered data.

Journal: Blood reviews
Published: May 19, 2026

Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact (D-IMPACT) Project.

Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact (D-IMPACT) Project.

Journal: Cancers
Published: April 08, 2026

Unmet needs and quality of life burden in chronic myeloid leukemia: results from a nationwide Italian real-world survey.

Unmet needs and quality of life burden in chronic myeloid leukemia: results from a nationwide Italian real-world survey.

Journal: Frontiers in oncology
Published: April 03, 2026

Beyond ATP: asciminib and the allosteric path in CML.

Beyond ATP: asciminib and the allosteric path in CML.

Journal: Blood
Published: March 26, 2026

Multidisciplinary characterization of rare MPL Y591 and R592 variants in myeloid disorders: from clinical correlation and literature-based evidence to in silico predictors and structural bioinformatics.

Multidisciplinary characterization of rare MPL Y591 and R592 variants in myeloid disorders: from clinical correlation and literature-based evidence to in silico predictors and structural bioinformatics.

Journal: Experimental hematology
Published: March 24, 2026

The Path Forward in MF: Small Molecules in the Limelight.

The Path Forward in MF: Small Molecules in the Limelight.

Journal: Cancers
Published: March 23, 2026

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study.

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study.

Journal: Cancer
Published: February 19, 2026

Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study.

Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study.

Journal: The oncologist
Published: December 23, 2025

Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis.

Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis.

Journal: Cancer
Published: December 16, 2025

CD20 Loss as a Mechanism of Resistance to Mosunetuzumab in Relapsed Follicular Lymphoma.

CD20 Loss as a Mechanism of Resistance to Mosunetuzumab in Relapsed Follicular Lymphoma.

Journal: Mediterranean journal of hematology and infectious diseases
Published: November 29, 2025

Retraction Note: Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs) induce apoptosis in K562 cells.

Retraction Note: Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs) induce apoptosis in K562 cells.

Journal: BMC cancer
Published: November 26, 2025
Showing 1-12 of 198

Last Updated: 09/26/2026